WHAT POSSIBILITIES ARE CURRENTLY AVAILABLE AFTER RENAL CARCINOMA (ORGAN CONFINED) DIAGNOSTICS FAILURE?

Czech version

Authors: J. Katolická
Authors‘ workplace: Onkologicko-chirurgické oddělení FN u svaté Anny, Brno
Published in: Urol List 2011; 9(4): 39-42

Overview

Targeted therapy has recently become the skeleton of metastatic renal carcinoma treatment. The major agens for metastatic renal cancer treatment include sunitinib, temsirolimus, pazopanib and bevacizumab/INF as the first line therapy, and everolimus as the second line therapy (after VEGF-TKI inhibitor) and sorafenib (after cytokine therapy); however the optimal sequence of the individual medicaments has not been defined. All the medicaments are associated with specific side effects, therefore before initiating the treatment it is necessary to consider the clinical conditions of the patient, all comorbidities and the toxicity profile of given agens.

Key words:
metastatic renal carcinomatargeted therapy

Sources

1. Zama IN, Hutson TE, Elson P et al. Sunitinib rechallange in metastatic renal cell carcinoma patients. Cancer 2010; 116(23): 5400–5406.

2. Rini BI, Cohen DP, Lu DR et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal carcinoma (mRCC) treated with sunitinib. 2010 ASCO Genitourinary Cancers Symposium, abstract 312.

3. Michaelson MD, Cohen DP, Li S et al. Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal carcinoma (mRCC) treated with sunitinib (SU). 2011 ASCO Genitourinary Cancer Symposium, abstract 1320.

4. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125–134.

5. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma (AVOREN): final analysis of overal survival. J ClinOncol 2010; 28(13): 144–150.

6. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J ClinOncol 2010; 28(6): 1061–1068.

7. Hudes G, Carducci M, Tomczak P et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl Med 2007; 356: 2271–2281.

8. Motzer R, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma – final results and analysis of prognostic factors. Cancer 2010; 116(18): 4256–4265.

9. National Institute for Health and Clinical Excellence. Final appraisal determination – sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. 2004.

10. Puzanov I. Sekvenční terapie renálního karcinomu. Farmakoterapie 2011; 7(2): 192–199.